🧵 Hemophilia A and B — 12 high-yield pearls for diagnosis, treatment, and perioperative care #HemeBoards #Hemophilia #HemeTwitter #MedTwitter 👇 ISTH ASH European Hematology Association Hem-Onc Fellows Network The Fellow On Call Blood Journals Portfolio Hemophilia Federation of America (HFA)

T-cell dysfunction during blinatumomab therapy in pediatric acute lymphoblastic leukemia ow.ly/gGSt50WEOFM #immunobiologyandimmunotherapy #lymphoidneoplasia

Outcomes of adult patients with newly diagnosed IDH-mutated AML treated with intensive chemotherapy and venetoclax Leukemia Journal nature.com/articles/s4137…

👉👉👉Delighted to share our group’s new work just out in Blood Advances | Preclinical work in #Tasquinomod in advanced MPN setting #MPNSM #leusm Lucia Masarova, MD Andrew Dunbar Naveen Pemmaraju, MD Prithviraj Bose Tapan Kadia Raajit Rampal, M.D.Ph.D. Sanam Loghavi, MD صنم لغوی 🔬🧬 ashpublications.org/bloodadvances/… MPNCo&D Congress

🧬 AML study (2010–2024, n=187): 1️⃣ TDT groups: 1–5d (70%), 6–10d (16%), 11+d (14%) 2️⃣ CR ↓ with 11+d delay (OR=0.32, p=0.003) 3️⃣ No OS difference on multivariate analysis 📌 Waiting for full profiling before induction is safe

👦👧 PLAT-02/03 trials in pediatric & YA B-ALL: 1️⃣ PLAT-02 (n=72): 89% MRD– CR, 1y LFS 71%, 2y 64%; better with low burden (91% vs 42%) 2️⃣ CRS 13%, neurotox 16% 3️⃣ PLAT-03 (n=19 T-APCs): safe, improved CAR persistence (20% vs 57% loss) 🔬 Serial CD19 antigen exposure promising